Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Even in the face of raising money? You do now that when dilution occurs shares are discounted by 20% to 30% right?
RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum
http://finance.yahoo.com/news/rxi-pharmaceuticals-corporation-selected-present-110200090.html
If Cytodyn was to uplist it would be in much better shape because Mabvax is still only in phase 1 trials. Cytodyn is in two phase 3 trials. Also Cytodyn is targeting a bigger market as well. I expect though a dilution to take place soon, and then a reverse split announcement later in the year. That would be a better time to buy.
Wanna know why? Because dilution is on its way. That S-3 form filed on August 26 has spooked investors. I would wait until they dilute first before buying shares.
Well not important to look at the count anyways as a reverse stock split will greatly reduces that number. Lets say for example - I'm guessing -- they go with a 1 for 10 that would put the float at 14 million shares total. Which is a small float. That's just one example.
I would agree with you if this was only in phase 2. The fact they are in two phase 3 trials and not uplisting is a disservice to shareholders. Most biotechs rise in anticpation of or during phase 3 results. Had this company only been in phase 2 currently then I would agree an uplist would be bad. But this is in phase 3, and many big funds want to buy this.
I'm waiting until the company does a reverse split and uplists to buy a position. I think it will head down on dilution news coming up, and possible reverse split news. I know the company wants to bring up share price organically but so far every positive news has been ignored by the wayside.
You do realize that the company is running both adjunct therapy -- combination and monotherapy right? That's two different phase 3 trials...... sigh for you.
Misiu is right. Pro 140 can be administered at home once a week. With the HIV drug from the Taiwan company patients are forced to go to the hospital to get infusions. What would you rather do? Drive one hour or so to get your treatment or just take a few seconds to inject yourself at home. not even close in comparison.
It needs an uplist to the NASDAQ IMO. Considering that it is in two phase 3 trials It should uplist. Most other small cap biotechs uplist with only phase 2 trials in process. I don't predict it will move much if they don't uplist. Either that or results of phase 3 come out. But phase 3 results for the adjunct therapy should take until July 2017 to September 2017 IMO. So at least one year, because they added the 100 patients for placebo control.
What I was saying is that they have to issue more shares and they have to dilute to run the phase 3. So when they dilute don't expect the share price to go higher. I think if someone wants to go all in for long-term they can wait till after the company dilutes first, then buy in long-term into CYDY. There is only one more dilution needed to carry the company well into next year for results in 2017. After the results (pending they are really good) won't need to dilute anymore. I'm sure they can find a partner at that point and the share price will be higher.
I told everyone to wait to buy in. I predict the dilution could potentially bring this down to the .60 - .80 area. Dilutions almost always happen at a 20% to 30% discount to market price. So the offering won't be priced at $1.08.
That means it is best to wait for the company to dilute first, have enough money to carry it to results/FDA approval. Once they dilute they should have cash well into 2018. That's why I pulled my profits out, I knew they would have to dilute again. Best time to buy is after they are done diluting.
I agree with you. I thought I read as well that they have enough cash till Q1 2017 or so. Even then didn't they hire Oppenheimer to find a strategic option? If a partner/buyer lined up? Why dilute more shares? Plus no PR or explanation from management as to why. Doesn't sit well with me either. Keeping small core position for long-term very few shares, but majority of money is out to buy other biotechs.
I agree. Right now after this dilution, I just don't see why it would be good to hold. Unless they find a partner. I don't see a buyout scenario. Otherwise why raise money? Plus even if they get started with another phase 3 study it will take 2 to 3 years for results to be readout. Just too much timeline here. of course good to hold a small core position, and use money elsewhere in the meantime.
yah but everything just got stretched much later. Isn't there a 100 patient placebo arm being added to the phase 3 monotherapy? So that is expected to start Q4 2016 and probably won't have results until Q1 2018 or later. The adjunct therapy may finish with results in 2017 though, but the filing will take many months as well. All in all too many delays good to hold a core position here for long term though.
But it would be more prudent to hold small core position now and then wait to buy more shares later when it drops.
Well I guess the good news is that if you want to pick up shares you can no wait till this drops more. Friday's news was all bad and lots of delays. So this will be a longer term buy and hold than anticipated. Not a bad thing but not a very good thing neither. But this gives chance for new entry points because the share price will drop to .70 to .80 now IMO>
Plus I forgot to add they still need cash to fund all the trials so they will have to raise more funds. That means possible dilution, and that means more burden on the share price.
On top of that, if and a big if they implement a r/s the stock price will fall on that announcement as not everyone stays in for a r/s. So plenty of time to buy back CYDY cheaper IMO.
I agree with you. Primary endpoint met on phase 3 BPH. That in itself takes the risk out. BPH is expected to be a $5 billion market by the year 2025. Prostate cancer trial showed 2 abilations or complete response meaning tumor gone completely --- cure. The other patients experience a partial response or partial clearance. The patients that didn't experience anything could have been because of dosing issues. That can be resolved.
I see $20 to $30 in the short term IMO.
Before end of 2016 is what they stated on CC. What that means? We have to wait and see. Could be October/Nov/Dec maybe. Just depends!
You missed the Conference call then. The CEO stated that they have received multiple requests for the cosmeceuticals compound. Said companies though want to see the results first. So once Rxi runs the consumer testing which should take about 5 to 6 months from when they start, then they already have interested parties lined up..............
Straight from the Conference call transcript:
Unidentified Analyst
Right. So do you anticipate being able to get a partner based upon the sunscreen test itself and possibly see get it into the market fairly soon?
Geert Cauwenbergh
The number of the companies that are into that space including some of the larger multinationals that are into the consumer space and are interested in pigmentation and management of pigmentation in people have expressed an interest in talking to us when we have those data available.
They have already received interest from larger multinationals -- think big pharma -- but they are awaiting for the consumer testing data. So that answers your marketing problem and partner problem.
Not Necessarily. If you read the CC transcript the final results for the scar trial, eye trial, and samcyprone won't happen until mid 2017. But those are for the final results.
the company revealed that before the end of the year they will release cohort 1 & 2 together with Cohort 3 & 4 with added doses as preliminary results/pictures. Also for the eye trial they will also release safety and early efficacy for that as well. So actually results will be available before then. Hopefully the scar results impress this time around. The last scar results showed a 68% improvement with RXI-109 treatment. My hope is to see this time an 85% to 90% improvement. That would be a game changer IMO, to improve scars by that much if that is the next result. We shall see what happens the next go around. GL to all
Yes that's true but Cosmecueticals don't require FDA approval, and it depends how much better their product is compared to all other hyperpigmentation cosmetic products.
What I like about scarring is that if Rxi gets that approved first, it will become the first drug to be approved by the FDA for Scarring. Meaning no competition whatsoever, because Rxi can make the therapeutic claim to doctors that it has been approved by the FDA. There are other scar products on the market, but they can't make any FDA approval claims. They also don't work as well as RXI-109 IMO.
But I see your point cosmecueticals is very huge opportunity for RXII. The best part is that Dr. Geert mentioned on the call that once they are done with consumer testing, which could take up to 6 months from when they start, they have interested parties in partnering.
Scarring is blockbuster -- Global market for scars is estimated $3 to $5 billion. That answers your question
I think you are right but I also believe it is best to wait to add a long position. They want to increase authorized shares at the upcoming meeting. So first I would wait for them to dilute, otherwise how would they fund all those phase 3 trials? So wait for dilution and warrants and then buy a big position. IMO the new dilution will probably knock down the price a little.
The increased dosing on the last one improved scars by up to 68% which was statistically significant to placebo, don't know what you are talking about. Also, each time according to the graph bar chart they added doses the scars improved. That means if the next batch of results for skin scarring sees 85 to 90% improvement that will be bullish IMO. But that should be doable considering the most recent scar results was 68% improvement. the added doses should boost that number higher.
One main problem. If the Board of Director hires a son as CEO despite qualifications, run don't walk away immediately. The fact is that the board of directors should have done their fiduciary duty and fired Gerald years ago back in 2014 when Lympro revenue never happened. AMBS is a train wreck in the making.
Not only that? How do we know that a complaint has been filed? he could have lied and made that up to make his article seem more appealing. It's disgusting.
Yes and they will get that $1 with another reverse stock split. Last one was in March 28th i believe. Hit a high of $9.30 per share down to where it is now....
Another one? Wow. Looks like before all is said and done investors will be left with 1 share of GBSN. The stock would have to hit 10,000 a share to break even.........LOL
I want to believe that it will go higher but day after day it has nothing but gone down since hitting $1.29 as a high to where it is now. I will probably sell the majority of my position leaving some in, but I will wait to buy back lower. Not because I don't believe in the company, because I do, but the trend and chart indicates a further decline. I don't want to be bearish, I actually want to see a bounce tomorrow just don't see it happening with the declining day after day. IMO it's smarter to take small loss now and wait to buy more shares lower. I don't know that it will go down to .80 like many suggest, but it is having a hard time holding at the $1 level and its showing every day CYDY trades.
Yes and remember those results are preliminary the patients have the option if they showed response in moving on to more doses of samcyprone from the slides. What we saw was a preliminary look, but statistically significant compared to placebo.
I'm against a buyout because the problem is that most companies only pay a 60 to 80% premium over current price. That would mean Rxi shareholders would get away with $5 to $6 a share and that would be bad. Most investors here need $20+ just to break even.
Good results for a 7 week treatment period, all patients going to 10 weeks as well.
" Greater than 50% clearance was observed in 47.6% of treated subjects
over the seven week treatment period"
Statistically significant over placebo
No need to worry just accumulate and enjoy the ride. With recruitment going from 300 patients down to 150 patients I expect results by May/June of 2017, maybe earlier.
yahoo finance shows 171k like you said. Also there seems to be huge buying around here at $1.02 so hopefully support holds around here and bounces back higher. But if you look below on this webpage you will see that there is huge short interest trying to drag it down.
http://otcshortreport.com/?index=CYDY&action=view
No, but that depends on how much royalty percentage was set up.
Pretty much, they don't have to wait 2 to 3 weeks for test, straight to dosing and enrollment. Gonna go much faster now
No No NO. the trial started october 2015. This is the recruitment of patients under the new protocol to recruit faster. They must have already had (I'm guessing) 80 to 100 patients)) Just now with the new protocol they can enroll faster. The phase 3 trial itself started October 2015, not now. This was a protocol change to enroll faster........Plus as noted a few weeks ago in the conference call the enrollment was reduced from 300 patients needed down to only 150 patients. Plus now they don't have to wait several weeks to see if the patient has R5 strain HIV tropism, they can be treated right away regardless. That speeds up testing and enrollment.......
Neither a good or bad thing, but it is okay. It just means not many buying but also not many selling. People holding on to shares waiting for the next piece of news.
Well the warts indication alone is probably around $200 to $400 million market opportunity. RXII trading at only $18 mil mkt cap is ridiculous IMO. That's not including the cosmescueticals and scarring.
well at least they will show proof of concept study in Warts for phase 2. Honestly even with the warts indication alone Rxi shouldn't be trading with a $18 mil market cap